LXEO
Lexeo Therapeutics, Inc.
Next earnings Aug 17, 2026 · consensus $-0.29 EPS
Last earnings +5.0% on 2026-05-11
$4.70
▼ -3.89%$4.70▲ +20.20%
over 1Y
L $3.67EODHDH $10.63
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.9%
1W-4.7%
1M-8.6%
3M-16.8%
YTD-51.1%
1Y+20.2%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.09x); but unprofitable (net margin -15284.6%).
Lexeo Therapeutics, Inc. shows $654K in FY2022 revenue, a -15284.6% net margin, and -40.5% ROE.
Sources: SEC EDGAR (CIK 0001907108, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 1:56:08 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.